title: An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco.
abstract: BACKGROUND
  The prevalence of type 2 diabetes is increasing dramatically in the Middle East and North Africa region. However, there are few trials that have determined the effect of antidiabetic treatment in an observational setting in these countries.
  
  
  METHODS
  This was a noninterventional study performed in Morocco in 2006-2007 and in the Middle East in 2005-2006 to observe the efficacy and safety of acarbose in patients with pretreated or untreated type 2 diabetes. Glycemic parameters (fasting blood glucose, one-hour postprandial blood glucose, and HbA1c) were recorded within a 3-month period. The observation period included an initial visit at the start of acarbose therapy and up to three follow-ups.
  
  
  RESULTS
  Acarbose was effective in reducing glycemic parameters in patients from Morocco (n = 1082) and the Middle East (n = 1737). The mean one-hour postprandial blood glucose decreased by 35.5% to 165.4 ± 47.9 mg/dL in the Middle East and by 35.5% to 179.0 ± 49.9 mg/dL in Morocco. Mean fasting blood glucose decreased by 30.8% to 126.6 ± 34.2 mg/dL (Middle East) and by 34.5% to 150.6 ± 47.1 mg/dL (Morocco). The absolute reduction in HbA1c was 1.3% in the Middle East (final value 7.4%) and 1.0% in Morocco (final value 7.5%). Overall, 107 patients (Middle East) and 26 patients (Morocco) experienced minor drug-related adverse events, which were mainly gastrointestinal. The tolerability of acarbose was rated as very good/good by 80.8% in the Middle East and by 68.6% in Morocco.
  
  
  CONCLUSIONS
  This study illustrates the efficacy and safety of acarbose in the treatment of type 2 diabetic patients in an observational setting.
authors: Al Ain Centre, Dubai, United Arab Emirates.
authors: Abdul R
authors: AR
authors: Shihabi
authors: Essam M
authors: EM
authors: Moussa
authors: Hania
authors: H
authors: Sobierajska
authors: Birgit
authors: B
authors: Schmidt
keywords: Glucobay®; Glucor®; acarbose; noninterventional; observational; type 2 diabetes
references: Diabetes Res Clin Pract. 2001 Jun;52(3):193-204
references: 11323089
references: Diabetes Care. 2011 Jan;34 Suppl 1:S11-61
references: 21193625
references: Arch Intern Med. 2004 Oct 25;164(19):2090-5
references: 15505121
references: Diabetes Res Clin Pract. 2011 Apr;92(1):57-64
references: 21251726
references: Int J Qual Health Care. 2005 Aug;17(4):281-6
references: 15831543
references: Clin Ther. 1998 Mar-Apr;20(2):257-69
references: 9589817
references: Diabetes Care. 1996 Jun;19(6):642-7
references: 8725865
references: Cardiovasc Diabetol. 2007 Aug 15;6:20
references: 17697384
references: Diabetes Care. 1999 Jun;22(6):960-4
references: 10372249
references: BMJ. 1993 Jul 31;307(6899):292-5
references: 8374375
references: Clin Drug Investig. 2005;25(10):651-9
references: 17532710
references: Diabetes Obes Metab. 2008 Mar;10(3):212-22
references: 18269636
references: Eur Heart J. 2004 Jan;25(1):10-6
references: 14683737
references: Cardiovasc Diabetol. 2010 Apr 21;9:15
references: 20409333
references: Drugs. 1992;44 Suppl 3:47-53
references: 1280577
references: Clin Invest Med. 1995 Aug;18(4):325-31
references: 8549020
references: Diabetologia. 2004 Mar;47(3):385-394
references: 14985967
references: Diabetologia. 1996 Dec;39(12):1577-83
references: 8960845
references: Diabetes Res Clin Pract. 2000 Sep;50(1):49-56
references: 10936668
references: Diabetes Care. 2004 May;27(5):1047-53
references: 15111519
references: Clin Ther. 2012 Jun;34(6):1221-36
references: 22560622
references: N Engl J Med. 2007 Jan 18;356(3):213-5
references: 17229948
references: Diabetes Nutr Metab. 2002 Jun;15(3):143-51
references: 12173728
references: Diabetes Care. 2005 Jan;28(1):154-63
references: 15616251
references: Arch Intern Med. 2001 Feb 12;161(3):397-405
references: 11176766